Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 19, 2009, Pages 7979-7984

  Chen, Xu ^a   Mitsutake, Norisato ^b   LaPerle, Krista ^a   Akeno, Nagako ^b   Zanzonico, Pat ^a   Longo, Valerie A ^a   Mitsutake, Shin ^b   Kimura, Edna T ^b   Geiger, Hartmut ^c   Santos, Eugenio ^d   Wendel, Hans G ^a   Franco, Aime ^a   Knauf, Jeffrey A ^a   Fagin, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

Allele copy number; Angiosarcoma; Costello syndrome; Papilloma; Senescence

Indexed keywords

ALLELE; AMELOBLAST; ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COSTELLO SYNDROME; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DISEASE COURSE; EMBRYO; GENE EXPRESSION; GENE NUMBER; IN VIVO STUDY; MOUSE; MUTATION RATE; NONHUMAN; ONCOGENE; PAPILLOMA; PRIORITY JOURNAL; SKIN PAPILLOMA;

ALLELES; ANIMALS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASMS; ONCOGENES; RAS PROTEINS; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

MUS;

EID: 66049085164     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900343106     Document Type: Article

References (43)

1. Esteban LM, et al. (2001) Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 21:1444-1452.
2. Plowman SJ, et al. (2003) While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol 23:9245-9250.
3. Johnson L, et al. (1997) K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 11:2468-2481.
4. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308.
5. To MD, et al. (2008) Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 40:1240-1244.
6. Prior IA, Muncke C, Parton RG, Hancock JF (2003) Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol 160:165-170.
7. Tuveson DA, et al. (2004) Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5:375-387.
8. Shaw AT, et al. (2007) Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 21:694-707.
9. Guerra C, et al. (2003) Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4:111-120.
10. Haigis KM, et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40:600-608.
11. Aoki Y, et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038-1040.
12. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y (2008) The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29:992-1006.
13. Lin AE, et al. (2002) Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet 111:115-129.
14. Kerr B, et al. (2006) Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 43:401-405.
15. Gripp KW, et al. (2006) HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 140:1-7.
16. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA (2006) HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140:8-16.
17. Gripp KW, et al. (2002) Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet 108:80-87.
18. Colby WW, Hayflick JS, Clark SG, Levinson AD (1986) Biochemical characterization of polypeptides encoded by mutated human Ha-ras1 genes. Mol Cell Biol 6:730-734.
19. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD (1984) Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312:71-75.
20. Schuhmacher AJ, et al. (2008) A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 118:2169-2179.
21. Cardiff RD, Leder A, Kuo A, Pattengale PK, Leder P (1993) Multiple tumor types appear in a transgenic mouse with the ras oncogene. Am J Pathol 142:1199-1207.
22. Hennekam RC (2003) Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 117:42-48.
23. Braun BS, et al. (2004) Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 101:597-602.
24. Rennel E, et al. (2003) Regulation of endothelial cell differentiation and transformation by H-Ras. Exp Cell Res 291:189-200.
25. Doi ST, Kimura M, Katsuki M (1994) Site-specific mutation of the human c-Ha-ras transgene induced by dimethylbenzanthracene causes tissue-specific tumors in mice. Jpn J Cancer Res 85:801-807.
26. Wakabayashi Y, Mao JH, Brown K, Girardi M, Balmain A (2007) Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 445:761-765.
27. Mo L, et al. (2007) Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 117:314-325.
28. Zhang Z, et al. (2001) Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29:25-33.
29. Diaz R, et al. (2002) The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 62:4514-4518.
30. Finney RE, Bishop JM (1993) Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science 260:1524-1527.
31. Boerrigter ME, Dolle ME, Martus HJ, Gossen JA, Vijg J (1995) Plasmid-based transgenic mouse model for studying in vivo mutations. Nature 377:657-659.
32. Geiger H, et al. (2006) Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood 107:3010-3011.
33. Denko N, Stringer J, Wani M, Stambrook P (1995) Mitotic and post mitotic consequences of genomic instability induced by oncogenic Ha-ras. Somat Cell Mol Genet 21:241-253.
34. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ (1994) The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci USA 91:5124-5128.
35. Saavedra HI, Fukasawa K, Conn CW, Stambrook PJ (1999) MAPK mediates RAS-induced chromosome instability. J Biol Chem 274:38083-38090.
36. Wani MA, Xu X, Stambrook PJ (1994) Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells. Cancer Res 54:2504-2508.
37. Agapova LS, et al. (1999) P53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints. Oncogene 18:3135-3142.
38. Knauf JA, et al. (2006) Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J Biol Chem 281:3800-3809.
39. Saavedra HI, et al. (2000) The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19:3948-3954.
40. Rassool FV, et al. (2007) Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res 67:8762-8771.
41. Bartkova J, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870.
42. Sarkisian CJ, et al. (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9:493-505.
43. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602.